Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
JournalJAMA Oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Neoplasms
Therapeutics
mechanistic target of rapamycin complex 1
TOR complex 2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer? / Unni, Nisha; Arteaga, Carlos L.

In: JAMA Oncology, 01.01.2019.

Research output: Contribution to journalComment/debate

@article{12d857aeebc54bffb5317182faef8f99,
title = "Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?",
author = "Nisha Unni and Arteaga, {Carlos L}",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamaoncol.2019.2525",
language = "English (US)",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?

AU - Unni, Nisha

AU - Arteaga, Carlos L

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85071526777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071526777&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.2525

DO - 10.1001/jamaoncol.2019.2525

M3 - Comment/debate

C2 - 31465107

AN - SCOPUS:85071526777

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

ER -